Pablo NENCLARES | Research Fellow | Clinical Oncologist | Head and Neck Unit / Radiotherapy and Imaging Team | Research profile
Kevin Harrington (@kevhar6763) / Twitter
Dr. Harrington on the KEYNOTE-048 Trial in Recurrent/Metastatic Head and Neck Cancer
Professor Kevin Harrington - The Institute of Cancer Research, London
GM herpes virus fights advanced cancers
RM Magazine - Winter 2022 by The Royal Marsden - Issuu
Royal Marsden staff among world's top influential researchers | The Royal Marsden Cancer Charity
SAB and I-O AB - T3 Pharma
World-first centre for recurrent head & neck cancer - Professor Christopher Nutting Oncology
World's first centre for recurrent head and neck cancer launched - Professor Christopher Nutting Oncology
Using Viruses to Treat Cancer | Prof Kevin Harrington | #SCIPEL 2015 | SCI - YouTube
Cancer: Scientists aim to double survival within a decade | The Independent
Dr. Harrington on the KEYNOTE-048 Trial in Recurrent/Metastatic Head and Neck Cancer
Professor Kevin Harrington, I [IMAGE] | EurekAlert! Science News Releases
Professor Kevin Harrington - The Institute of Cancer Research, London
Professor Kevin Harrington to star in BBC2's Trust me, I'm a Doctor - The Institute of Cancer Research, London
Professor Kevin Harrington - The Institute of Cancer Research, London
Professor Kevin Harrington - The Institute of Cancer Research, London
Will Immunotherapy Put Head and Neck Surgeons Out of Business? – Semon Lectures
Game-changing drug doubles head and neck cancer survival | The Royal Marsden
BBC Two - Trust Me, I'm a Doctor, Series 3, Episode 3 - Could viral immunotherapy be a revolution in cancer treatment?
The ICR on Twitter: "🧬 The ICR's Professor Kevin Harrington and his team are using viral #Immunotherapy to harness the body's immune system to kill cancer. See their research with T-VEC, a
The Royal Marsden NHS Foundation Trust on Twitter: "Huge congratulations Professors David Cunningham, Johann De Bono, Kevin Harrington, Nicholas Turner, Mitch Dowsett, James Larkin! #HighlyCited2021" / Twitter
